SECAUCUS, N.J., Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies.The selection is based on nine key attributes related to corporate reputation, including quality of products and services, innovation, community responsibility, s ...

Quest Diagnostics (DGX 5.62%) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades. The healthcare testing specialist's share price was up by more than 5% in late afternoon action, well ahead of the S&P 500 index's 0.8% gain at that point in the day. Notching a double beatThe main reason for the bullish move wasn't hard to figure out -- Quest posted its fourth-quarter and full-year 2024 results this morning. Investors were particularly impressed ...

Quest Diagnostics saw robust growth in earnings and revenue, surpassing expectations for Q4 2024.Quest Diagnostics (DGX 5.67%), a leader in diagnostic testing and information services, released its fourth quarter results on Jan. 30. The company reported a notable quarter with adjusted earnings per share (EPS) of $2.23, surpassing the analyst projection of $2.18. Additionally, revenue reached $2.62 billion, exceeding the expected $2.58 billion. Overall, Quest had a successful quarter, driven by strategic acq ...

Quest Diagnostics Inc.’s (DGX) fourth-quarter 2024 adjusted earnings per share (EPS) of $2.23 beat the Zacks Consensus Estimate by 1.8%. The metric also exceeded the year-ago adjusted figure by 3.7%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjus ...

Quest Diagnostics (DGX) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.83%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $2.26 per share when it actually produced earnings of $2.30, delivering a surprise of 1.77%.Over the last four qua ...

Exhibit 99.1 Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share SECAUCUS, N.J., January 30, 2025 -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2024. "In the fourth quarter, we delivered impressive revenue growth of nearly 15%, including approximat ...

Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023 Full year revenues of $9.87 billion, up 6.7% from 2023 Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023 Full year 2025 reported diluted EPS expected to be between $8.34 and $8.59; and adjusted diluted EPS expected to be between $9.55 and $9.80S ...

文章核心观点 2025年1月27日诊断信息服务领先提供商Quest Diagnostics完成对美国领先非营利医疗系统和学术医疗中心之一University Hospitals部分资产的收购 财务条款未披露 收购后Quest将扩大其在俄亥俄州的检测菜单、患者服务点网络和健康保险覆盖范围 [1][2] 收购情况 - Quest Diagnostics完成对University Hospitals部分资产的收购 财务条款未披露 [1] - 收购后Quest将扩大在俄亥俄州的检测菜单、患者服务点网络和健康保险覆盖范围 [2] - Quest位于俄亥俄州特温斯堡和宾夕法尼亚州匹兹堡的实验室将为使用其实验室服务的University Hospitals的供应商和患者进行检测 University Hospitals将继续通过其医院实验室提供所有住院和部分门诊检测 [2] Quest Diagnostics公司介绍 - Quest Diagnostics通过实验室检测结果提供诊断见解 助力改善健康状况 每年为三分之一的美国成年人以及一半的美国医生和医院提供服务 拥有超5万名员工 [3] University Hospitals公司介绍 - University Hospitals成立于1866年 通过综合网络为患者服务 旗下有超20家医院、50多个医疗中心和门诊设施以及200多个医生办公室 位于俄亥俄州北部16个县 [4] - 该系统旗舰学术医疗中心与多所大学有合作关系 主校区包含多家知名医院 拥有多个临床和研究项目 超3000项正在进行的临床试验和研究 是俄亥俄州东北部最大雇主之一 拥有超3万名员工 [4]

文章核心观点 - 奎斯特诊断公司（Quest Diagnostics）将于1月30日开盘前公布2024年第四季度财报，市场对其营收和每股收益有增长预期，公司多方面业务表现及战略举措有望推动业绩提升，同时还推荐了其他几只可能实现盈利超预期的医疗科技股 [1][3] 财报发布信息 - 奎斯特诊断公司将于1月30日市场开盘前发布2024年第四季度财报 [1] 过往业绩表现 - 公司上一季度调整后每股收益为2.30美元，超出Zacks共识预期1.77%，过去四个季度均超盈利预期，平均超预期幅度为3.41% [2] 第四季度业绩预期 - Zacks对公司2024年第四季度营收的共识预期为25.7亿美元，同比增长12.4%；每股收益预计增长1.9%至2.19美元 [3] - 过去60天，公司第四季度盈利预期维持在2.19美元不变 [4] 影响第四季度业绩的因素 业务增长驱动 - 诊断信息服务（DIS）预计因核心医生和医院渠道表现强劲而实现显著增长，医生实验室服务受益于新客户和业务拓展，特别是先进诊断服务利用率提高 [5] - 多个临床领域有望在第四季度实现强劲营收，如脑健康领域受AD - Detect血液检测推动，分子基因组学和肿瘤学推进Haystack MRD血液检测全国推广，女性健康业务受益于产前和遗传检测及生殖道感染检测需求，自身免疫疾病检测需求高 [6] 收购助力 - 公司在2024年10月收购俄亥俄健康（OhioHealth）部分实验室资产，9月收购阿丽娜健康（Alina Health），收购LifeLabs有助于拓展加拿大市场 [7] 医保及合作推动 - 医疗保险优势计划的高业务量和收入增长推动公司第四季度营收，公司还通过与健康计划合作拓展新地区 [8] 医院业务需求 - 医院专业实验室人员招聘难题持续推动参考检测业务需求，促使医院利用公司先进诊断产品组合，而非自建能力 [9] 线上业务增长 - questhealth.com上消费者发起的检测业务在第四季度有望实现强劲营收和高回头客率 [9] 运营效率提升 - 公司战略运用自动化和人工智能改善质量、服务、效率和员工体验，如堪萨斯州莱内萨高度自动化实验室的启用、克利夫顿实验室自动样本处理试点及与豪洛捷（Hologic）的合作 [11] - 公司Invigorate计划预计实现3%的年度成本节约目标 [11] 模型预测结果 - 公司DIS收入在待报告季度预计同比增长11.7% [10] - 2024年第四季度，公司非GAAP基础上的营业收入和EBITDA预计分别同比增长20.7%和20.1% [12] 盈利预测模型分析 - 公司Zacks排名为2（买入），但盈利ESP为0.00%，根据模型，这种情况超预期盈利的可能性不高 [13] 其他医疗科技股推荐 美西莫（Masimo） - 盈利ESP为+4.05%，Zacks排名为2，将于2月25日公布2024年第四季度财报 [14] - 过去四个季度盈利均超预期，平均超预期幅度为17.10%，第四季度每股收益预计同比增长14.4% [15] 美力敦医疗系统（Merit Medical Systems） - 盈利ESP为+3.03%，Zacks排名为2，定于2月25日公布2024年第四季度财报 [15] - 过去四个季度盈利均超预期，平均超预期幅度为6.42%，第四季度每股收益预计同比增长2.47% [16] 伊克塞利斯（Exelixis） - 盈利ESP为+2.99%，Zacks排名为2，预计2月4日公布2024财年第四季度财报 [16] - 过去四个季度中三次盈利超预期，一次未达预期，平均超预期幅度为26.52%，第四季度每股收益预计同比飙升51.5% [17]

Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J., Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Adrienne L. Brott, an accomplished quality and regulatory affairs healthcare leader, has been named senior vice president and chief quality and regulatory affairs officer. Adrienne Brott has joined Quest Diagnostics as Senior Vice President and Chief Quality a ...